

Systemic Sclerosis (Scleroderma): Market Assessment, Epidemiology & Market Forecast-2028

<https://marketpublishers.com/r/S80F8560544EN.html>

Date: February 2019

Pages: 100

Price: US\$ 4,500.00 (Single User License)

ID: S80F8560544EN

Abstracts

CmaxInsight's "Systemic Sclerosis (Scleroderma): Market Assessment, Epidemiology & Market Forecast-2028" report provides an overview of the disease and market size of Systemic Sclerosis (Scleroderma) for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers epidemiology of Systemic Sclerosis (Scleroderma) from 2018 to 2028 segmented by seven major markets market along with market drivers, market barriers and unmet medical needs of this indication.

Research Scope

Systemic Sclerosis (Scleroderma) Overview and Treatment Landscape

The report provides comprehensive information of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Systemic Sclerosis (Scleroderma) in the United States, Europe, and Japan are also covered.

Systemic Sclerosis (Scleroderma) Epidemiology

This section of the report provides the country-specific information of historical and current patient pool and offers forecasted value for prevalent/ incident cases, along with diagnosed and treatable patient pool.

Systemic Sclerosis (Scleroderma) Marketed and Emerging Drug Landscape

A snapshot on the marketed and pipeline emerging drugs, along with comprehensive insight on emerging treatments based on their safety & efficacy results, mechanism of action, route of administration, therapeutic potential, regulatory success, launch dates, and other factors.

This section also covers latest news which includes agreements and collaborations, approvals, patent details and other major breakthroughs.

Systemic Sclerosis (Scleroderma) Market Size and Segmentation

This segment of the report focuses on key question: “What is the size of the total & addressable market for Systemic Sclerosis (Scleroderma)”? This key question will help to answer whether the market is big enough to be interested in your business. Relevant and detailed patient segmentations are provided for each Indication, enabling to evaluate the commercial potential of the market.

Systemic Sclerosis (Scleroderma) Market Trends and Opportunities

Identify market trends and the opportunities by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Systemic Sclerosis (Scleroderma) Unmet Needs

Discover the significant current and future unmet needs for the Systemic Sclerosis (Scleroderma). Market requirements vary with different countries and geographies.

Methodologies

Our experts synthesize information from proprietary databases, syndicated reports, primary research and secondary data, such as company reports, press releases, published peer-reviewed journal articles, disease registries, and general news media to provide a complete picture of your market. Our approach ensures that every data point and inference goes through multiple validations while leveraging a variety of sources to formulate market and opportunity size.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Systemic Sclerosis (Scleroderma) market.

The report provides detailed historical and forecasted epidemiological data of Systemic Sclerosis (Scleroderma) in the 7MM from 2018-2028.

Organize sales and marketing efforts by identifying the best opportunities for Systemic Sclerosis (Scleroderma) in US, Europe and Japan.

To understand the future market competition in the global Systemic Sclerosis (Scleroderma) and insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

Contents

1. REPORT INTRODUCTION

2. SYSTEMIC SCLEROSIS (SCLERODERMA) MARKET OVERVIEW AT GLANCE

3. DISEASE BACKGROUND AND OVERVIEW: SYSTEMIC SCLEROSIS (SCLERODERMA)

3.1. Introduction

3.2. Signs and Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnostic Landscape

3.6.1. Diagnostic Practices

3.6.2. Diagnostic Criteria

3.6.3. Diagnostic Recommendations

3.7. Treatment Landscape

3.7.1. Current Treatment Practices

3.7.2. Treatment Algorithm

3.7.3. Treatment Recommendations

4. SYSTEMIC SCLEROSIS (SCLERODERMA) EPIDEMIOLOGY

4.1. Key Findings

4.2. Assumptions & Rationale

4.3. 7MM Epidemiology

5. EPIDEMIOLOGY OF SYSTEMIC SCLEROSIS (SCLERODERMA) BY COUNTRIES

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)

5.1.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*

5.1.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*

5.1.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)

5.1.6. Treatable Cases of Systemic Sclerosis (Scleroderma)

5.2. Germany

- 5.2.1. Assumptions and Rationale
- 5.2.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
- 5.2.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
- 5.2.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
- 5.2.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
- 5.2.6. Treatable Cases of Systemic Sclerosis (Scleroderma)
- 5.3. France
 - 5.3.1. Assumptions and Rationale
 - 5.3.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 5.3.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 5.3.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 5.3.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 5.3.6. Treatable Cases of Systemic Sclerosis (Scleroderma)
- 5.4. United Kingdom
 - 5.4.1. Assumptions and Rationale
 - 5.4.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 5.4.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 5.4.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 5.4.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 5.4.6. Treatable Cases of Systemic Sclerosis (Scleroderma)
- 5.5. Spain
 - 5.5.1. Assumptions and Rationale
 - 5.5.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 5.5.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 5.5.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 5.5.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 5.5.6. Treatable Cases of Systemic Sclerosis (Scleroderma)
- 5.6. Italy
 - 5.6.1. Assumptions and Rationale
 - 5.6.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 5.6.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 5.6.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 5.6.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 5.6.6. Treatable Cases of Systemic Sclerosis (Scleroderma)
- 5.7. Japan
 - 5.7.1. Assumptions and Rationale
 - 5.7.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 5.7.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 5.7.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*

5.7.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)

5.7.6. Treatable Cases of Systemic Sclerosis (Scleroderma)

6. UNMET NEEDS

7. MARKETED DRUGS

7.1. Drug

7.1.1. Product Description

7.1.2. Mechanism of Action

7.1.3. Regulatory Milestones

7.1.4. Safety and Efficacy

7.1.5 Side-Effects

7.1.6. Product Profile

7.1.7. Sales

7.1.8. Patent Data

8. EMERGING DRUGS

8.1. Drug

8.1.1. Product Description

8.1.2. Clinical Trial Information and Results

8.1.3. Product Development Activity

8.1.4. Regulatory Milestones

8.1.5. Product Profile

8.1.6. Expected Launch Date

9. COUNTRY SPECIFIC MARKET ANALYSIS

9.1. 7 Major Market Analysis

9.1.1. 7 Major Market Size

9.1.2. Therapy Wise Market Size

9.2. United States Market Analysis

9.2.1. United States Market Size

9.2.2. Therapy Wise Market Size

9.3. Germany Market Analysis

9.3.1. Germany Market Size

9.3.2. Therapy Wise Market Size

9.4. France Market Analysis

- 9.4.1. France Market Size
- 9.4.2. Therapy Wise Market Size
- 9.5. United Kingdom Market Analysis
 - 9.5.1. United Kingdom Market Size
 - 9.5.2. Therapy Wise Market Size
- 9.6. Spain Market Analysis
 - 9.6.1. Spain Market Size
 - 9.6.2. Therapy Wise Market Size
- 9.7. Italy Market Analysis
 - 9.7.1. Italy Market Size
 - 9.7.2. Therapy Wise Market Size
- 9.8. Japan Market Analysis
 - 9.8.1. Japan Market Size
 - 9.8.2. Therapy Wise Market Size

10. MARKET DRIVERS

11. MARKET BARRIERS

12. MARKET OPPORTUNITIES

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM

Table 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States

Table 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*

Table 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*

Table 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States

Table 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States

Table 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany

Table 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*

Table 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*

Table 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany

Table 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany

Table 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France

Table 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*

Table 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*

Table 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France

Table 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France

Table 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy

Table 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*

Table 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*

Table 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy

Table 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy

Table 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain

Table 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*

Table 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*

Table 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain

Table 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain

Table 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK

Table 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*

Table 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*

- Table 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
- Table 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
- Table 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Table 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Table 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Table 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Table 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Table 38: Marketed Drugs
- Table 39: Pipeline Drugs
- Table 40: 7MM- Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 41: 7MM- Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 42: 7MM- Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 43: United States-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 44: United States-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 45: United States-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 46: Germany-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 47: Germany-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 48: Germany-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 49: France-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 50: France-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 51: France-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 52: Italy-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 53: Italy-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 54: Italy-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 55: Spain-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Table 56: Spain-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Table 57: Spain-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Table 58: UK-Market Size of Systemic Sclerosis (Scleroderma) in USD MM

Table 59: UK-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Table 60: UK-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Table 61: Japan-Market Size of Systemic Sclerosis (Scleroderma) in USD MM

Table 62: Japan-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Table 63: Japan-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

*Indication Specific

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States

Figure 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*

Figure 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*

Figure 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States

Figure 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States

Figure 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany

Figure 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*

Figure 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*

Figure 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany

Figure 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany

Figure 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France

Figure 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*

Figure 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*

Figure 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France

Figure 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France

Figure 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy

Figure 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*

Figure 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*

Figure 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy

Figure 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy

Figure 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain

Figure 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*

Figure 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*

Figure 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain

Figure 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain

Figure 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK

Figure 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*

Figure 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*

- Figure 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
- Figure 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
- Figure 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Figure 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Figure 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Figure 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Figure 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Figure 38: Marketed Drugs
- Figure 39: Emerging Drugs
- Figure 40: 7MM- Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 41: 7MM- Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 42: 7MM- Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 43: United States-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 44: United States-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 45: United States-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 46: Germany-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 47: Germany-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 48: Germany-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 49: France-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 50: France-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 51: France-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 52: Italy-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 53: Italy-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 54: Italy-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 55: Spain-Market Size of Systemic Sclerosis (Scleroderma) in USD MM
- Figure 56: Spain-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM
- Figure 57: Spain-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Figure 58: UK-Market Size of Systemic Sclerosis (Scleroderma) in USD MM

Figure 59: UK-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Figure 60: UK-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Figure 61: Japan-Market Size of Systemic Sclerosis (Scleroderma) in USD MM

Figure 62: Japan-Market Share Systemic Sclerosis (Scleroderma) by Therapies in USD MM

Figure 63: Japan-Market Sales of Systemic Sclerosis (Scleroderma) by Therapies in USD MM

*Indication Specific

I would like to order

Product name: Systemic Sclerosis (Scleroderma): Market Assessment, Epidemiology & Market Forecast-2028

Product link: <https://marketpublishers.com/r/S80F8560544EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S80F8560544EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

